Role of clopidogrel loading dose in patients with stsegment. Safety and efficacy of high versus lowdose aspirin after primary percutaneous coronary intervention in stsegment elevation myocardial infarction. Ami the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial. Final 3year results from a multicentre, randomised controlled trial lancet. Paclitaxeleluting stents versus baremetal stents in acute. Mortality reduction with bivalirudin only partially due to bleeding. Effect of short procedural duration with bivalirudin on increased. The horizonsami harmonizing outcomes with revascularization. Patients with abs were identified, based on the mayo clinic diagnostic criteria, from those enrolled into the horizons. Jan 30, 2010 the 12month results of horizons ami oct 3, p 11491 show that, in patients with stsegmentelevation myocardial infarction stemi undergoing primary percutaneous coronary intervention pci, anticoagulation with bivalirudin reduced net adverse clinical events and major bleeding at 1 year compared with heparin plus a glycoprotein iibiiia inhibitor. The landmark horizons ami trial, sponsored by crf, is expected to significantly impact the way that patients are treated. In the harmonizing outcomes with revascularization and stents in acute myocardial infarction horizonsami randomized clinical trial.
Washington, dc bivalirudin has now proved itself in acutemi patients undergoing primary angioplasty, results from the horizons ami trial indicate. Heparin plus a glycoprotein iibiiia inhibitor versus bivalirudin monotherapy and paclitaxeleluting stents versus baremetal stents in acute myocardial infarction horizonsami. Previous trials are limited by serious shortcomings in trial design, and therefore fail to effectively conclude that tra adds a survival benefit in patients undergoing ppci. We assessed allcause and cardiac mortality, nonfatal mi, tvr, stent thrombosis, ischemic stroke, noncabg related major bleeding and net adverse clinical events. Correlation of admission heart rate with angiographic and. Bivalirudin for primary percutaneous coronary intervention in. Horizonsami trial provides superior outcomes data at. Harmonizing outcomes with revascularization and stents in. Final 3 year results from the landmark horizons ami trial published in the lancet june 2011 data from the landmark horizons ami clinical trial demonstrated that the administration of the. Stone, md in the horizons ami trial, the outcomes provide definitive evidence that, in patients with ami, drugeluting stents were superior in efficacy to baremetal stents and had a comparable safety profile at one year, said gregg w. The 12month results of horizonsami oct 3, p 11491 show that, in patients with stsegmentelevation myocardial infarction stemi undergoing primary percutaneous coronary intervention pci, anticoagulation with bivalirudin reduced net adverse clinical events and major bleeding at 1 year compared with heparin plus a glycoprotein iibiiia inhibitor.
The medicines company today reported a presentation of a pooled analysis of 5,800 patients in the euromax and horizons ami. Clinical trials center, cardiovascular research foundation, new york, new york. The two primary end points of the study were major bleeding and combined adverse clinical events. Segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. A criticism of both the acuity and horizonami trials is that both were conducted in an openlabel manner which may have influenced study. The trial will also compare delays to reperfusion between the two strategies. The design, inclusion and exclusion criteria, and results of the horizonsami trial have been previously published. A large prospective randomized trial of des vs bms in patients with stemi gregg w. To assess the association of dual antiplatelet therapy dapt use and longterm clinical outcomes in patients undergoing primary stenting for stsegment elevation myocardial infarction stemi. Methods we compared 3year outcomes in patients who were prescribed highdose 200 mg daily versus lowdose.
Safety and efficacy of high versus lowdose aspirin after. Horizons ami harmonizing outcomes with revascularization and stents in acute myocardial. The harmonizing outcomes with revascularization and stents in acute myocardial infarction horizons ami trial was a prospective, openlabel, multicenter, controlled trial involving patients with. In this regard, there are important differences in trial designs. The horizons ami harmonizing outcomes with revascularization and stents in acute myocardial infarction trial. In the horizons ami trial, patients with acute stsegment elevation myocardial infarction stemi undergoing percutaneous coronary intervention pci who were treated with the thrombin inhibitor bivalirudin had substantially lower 30day rates of major haemorrhagic complications and net adverse clinical events than did patients assigned to heparin plus a glycoprotein iibiiia inhibitor gpi. Horizons ami trial data to be presented at tct 2007. Correlation of admission heart rate with angiographic and clinical outcomes in patients with right coronary artery stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Bivalirudin for primary percutaneous coronary intervention. Pdf predictors of suboptimal timi flow after primary. Results of the horizons ami trial, reported in 2008 and 2011, 1, 2 demonstrated that patients undergoing primary percutaneous coronary interventions pcis who received aspirin, clopidogrel, and the direct thrombin inhibitor bivalirudin had significantly fewer major hemorrhagic complications and lower allcause mortality than patients who received unfractionated heparin plus a glycoprotein iib. Home journal of the american heart association vol.
We sought to identify clinical, electrocardiographic ecg, and angiographic characteristics that are predictive of 3. The clinical characteristics of patients with increasing duration of sbt are summarized intable 1. The harmonizing outcomes with revascularization and stents in acute myocardial infarction horizonsami trial was a prospective, openlabel, multicenter, controlled trial involving patients with. Death from noncardiac causes included bleedingrelated death. Horizons ami trial, 291 patients were excluded from the present study, including 143 patients treated with thienopyridines before the randomization, pafigure 1 flow chart of the present study enrollment and followup of the patients pts in the trial. Heparin plus a glycoprotein iibiiia inhibitor versus bivalirudin monotherapy and paclitaxeleluting stents versus baremetal stents in acute myocardial infarction horizons ami. Revascularization and stents in acute myocardial infarction. Article information, pdf download for the prognostic importance of. Data from the landmark horizons ami clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a. Prognostic impact of a chronic total occlusion in a non. The prognosis of patients with acute myocardial infarction ami has been considerably improved following the introduction of reperfusion therapies. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction horizonsami. Horizonsami the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial.
The original horizons ami trial established bivalirudin as an essential acute therapy to improve both early and late outcomes in patients with heart attack, and demonstrated that taxus drugeluting. Horizons ami harmonizing outcomes with revascularization and stents in acute myocardial infarction trial have been previously published. Customers affiliates powerpointtutorial videotour infographics. Intracoronary abciximab and aspiration thrombectomy in. Twoyear data from the trial will also be presented as a late breaking. Horizons ami the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial. The horizons ami trial was an international, multicenter, prospective, openlabel, randomized study designed to examine the safety and efficacy of bivalirudin monotherapy compared with ufh plus routine gpis, and the paclitaxeleluting taxus stent compared with a bare metal express 2 stent in patients with stemi undergoing primary pci. Aug 07, 2012 horizons ami harmonizing outcomes withrevascularization and stents in acute myocardial infarctiongw stone columbia university medical center cardiovascular research foundation, nytct 2007 meeting population. Harmonizing outcomes with revascularization and stents in acute myocardial infarction trial, 3,602 stemi patients were randomized to bivalirudin n 1,800 or heparin plus a gpi n 1,802. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding. Stone md columbia university medical center cardiovascular research foundation.
In the horizons ami trial, the outcomes provide definitive evidence that, in patients with ami, drugeluting stents were superior in efficacy to baremetal stents and had a comparable safety profile at one year, said gregg w. The inclusion and exclusion criteria are included as well as the primary and secondary endpoints. Followup data from the horizons ami trial continue to show that, in patients with ami, paclitaxeleluting stents were superior in efficacy to baremetal stents and had a comparable safety. In the main horizonsami harmonizing outcomes with revascularization and stents in acute myocardial infarction trial, 3,602 stemi patients were randomized to bivalirudin n 1,800 or heparin plus a gpi n 1,802. Bivalirudin during primary pci in acute myocardial infarction nejm. Death from cardiac causes was defined as death due to acute myocardial infarction, cardiac perforation or pericardial tamponade, arrhythmia or conduction abnormality, stroke, procedural complications, or any death for which a cardiac cause could not be ruled out. Paclitaxeleluting stents versus baremetal stents in. Clinical profile and impact of family history of premature. Horizonsami trial, harmonizing outcomes with revascularization and stents in acute myocardial infarction.
Patients with greater sbt were older and were more likely to be women, have diabetes mellitus, have prior angina, and have longer dbt, but were less likely to have postprocedural timi. Boston scientific welcomes publication of horizons ami. Pdf bivalirudin in patients undergoing primary angioplasty. Bivalirudin vs heparin in acute myocardial infarction jama. Request pdf on nov 1, 2008, luigi oltrona visconti and others published the horizonsami trial find, read and cite all the research you need on researchgate. Utility of postprocedural anticoagulation after primary pci for stemi. Whether the dose of aspirin affects longterm patient outcomes is unknown. Horizonsami harmonizing outcomes with revascularization and stents in acute myocardial infarction trial have been previously published. Horizonsami trial data shows 43 percent mortality reduction. It is the largest study to focus on the appropriate use of anticoagulation medications and stents in patients experiencing stemi and undergoing primary percutaneous coronary intervention pci, commonly known as angioplasty. Stemi from the harmonizing outcomes with revascularization and stents in acute myocardial infarction horizons. Final 3 year results from the landmark horizonsami trial. Quantitative angiography was performed by a core laboratory to identify the frequency and severity of coronary artery disease.
The horizons ami trial is cofunded by a grant from the medicines company. Role of clopidogrel loading dose in patients with st. Horizons ami trial demonstrates superior outcomes with. More recently, the horizons ami randomized, openlabel, multicenter trial has compared the efficacy and safety of bivalirudin alone versus ufh plus a gpi in 3602 patients with stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention. In the multicenter harmonizing outcomes with revascularization and stents in acute myocardial infarction horizons ami trial, 9 procedural anticoagulation with bivalirudin without a postpci infusion reduced 30day major bleeding and net adverse clinical events at the cost of an increased rate of acute horizons ami the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial. Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for stelevation myocardial infarction. The design, inclusion and exclusion criteria, and results of the horizons ami trial have been previously published. Harmonizing outcomes with revascularization and stents in acute. We therefore investigated the impact of mvd with and without a cto in a nonira on markers of reperfusion and 3year mortality in patients presenting with stemi and treated with primary pci in the largescale randomized horizonsami harmonizing outcomes with revascularization and stents in acute myocardial infarction trial. Horizons ami trial data to be presented at tct 2007 cardiovascular research foundationsponsored study is the largest ever to examine anticoagulation therapy and drugstent insertion in patients. Horizons ami harmonizing outcomes withrevascularization and stents in acute myocardial infarctiongw stone columbia university medical center cardiovascular research foundation, nytct 2007 meeting population.
The cardiovascular research foundation announces initiation. Horizons ami was a prospective, randomized trial of paclitaxeleluting stents pes vs. Final 3year results from the landmark horizonsami trial. Sep 21, 2009 san francisco, ca september 21, 2009 two subset analyses from the landmark horizons ami trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a gp iibiiia inhibitor in patients with stsegment myocardial infarction stemi who have disease of the left anterior descending artery lad, while in stemi patients at highe. A total of 1089 stemi patients enrolled in the horizons ami trial had baseline bnp levels measured in the emergency room as part of the study protocol.
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction horizons ami. The horizonsami trial was an international, multicenter, prospective, openlabel, randomized study designed to examine the safety and efficacy of bivalirudin monotherapy compared with ufh plus routine gpis, and the paclitaxeleluting taxus stent compared with a bare metal express 2 stent in patients with stemi undergoing primary pci. Cardiovascular disease is the leading cause of death in the us. Predictors of suboptimal timi flow after primary angioplasty for acute myocardial infarction. In the horizons ami trial, 3,602 patients with ami undergoing primary pci were prospectively randomized to unfractionated heparin plus routine use of glycoprotein gp iibiiia inhibitors versus the direct thrombin inhibitor bivalirudin plus provisional use of gp iibiiia inhibitors reserved for predefined thrombotic complications. Bivalirudin in patients undergoing primary angioplasty for. In the horizons ami trial, patients with acute stsegment elevation myocardial infarction stemi undergoing percutaneous coronary intervention pci who were treated with the thrombin inhibitor bivalirudin had substantially lower 30day rates of major haemorrhagic complications and net adverse clinical events than did patients. Bivalirudin enhances longterm survival in patients with stelevation myocardial infarction undergoing angioplasty. Oneyear results from horizonsami trial reported at tct 2009. Incidence and angiographic characteristics of patients. Mar 27, 2012 the cardiovascular research foundation crf today announced the initiation of the horizons ami ii randomized trial, evaluating promus element platinumchromium everolimuseluting stents versus.
1485 1173 877 1223 1349 301 775 588 1258 163 117 1019 237 740 948 587 1530 101 1220 1568 1432 1133 1252 776 1112 424 765 816 710 1070 1211 1425 938 1306 547 795 1003 76 850 799